ABCELLERA BIOLG (ABCL)
(Delayed Data from NSDQ)
$4.24 USD
-0.23 (-5.15%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $4.21 -0.03 (-0.71%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, AbCellera Biologics Inc. has a market cap of $1.33B, which represents its share price of $4.47 multiplied by its outstanding shares number of 298.42M. As a small-cap company, ABCL's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
ABCL 4.24 -0.23(-5.15%)
Will ABCL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ABCL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ABCL
AbCellera Biologics Inc. (ABCL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Strength Seen in ABCELLERA BIOLG (ABCL): Can Its 15.0% Jump Turn into More Strength?
ABCL: What are Zacks experts saying now?
Zacks Private Portfolio Services
ABCELLERA BIOLG (ABCL) Upgraded to Buy: Here's Why
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates
AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Misses Revenue Estimates
Other News for ABCL
AbCellera: Just Another Biotech Stock
Galaxy Digital, Blaize Holdings, Verizon And Other Big Stocks Moving Higher On Monday
AbCellera Biologics (ABCL) Receives Price Target Upgrade from KeyBanc | ABCL Stock News
AbCellera Biologics (ABCL) Rated Outperform by Leerink Partners | ABCL Stock News
AbCellera assumed with an Outperform at Leerink